Pouze pro profesionální použití

Herpesviruses

Cytomegalovirus

Cytomegalovirus (CMV, HHV-5) is a DNA herpesvirus characterized by lifelong persistence and the ability to reactivate.

Cytomegalovirus

O patogenu

Cytomegalovirus (CMV, HHV-5) is a DNA herpesvirus characterized by lifelong persistence and the ability to reactivate. In immunocompetent individuals, primary infection is often asymptomatic or presents as a mononucleosis-like syndrome with prolonged fever, fatigue, lymphadenopathy, atypical lymphocytes and, in some cases, hepatitis. In patients with impaired cellular immunity, including transplant recipients, patients with hematological malignancies, and those with advanced HIV infection, CMV may cause severe organ involvement, most commonly pneumonia, gastrointestinal disease such as esophagitis or colitis, and retinitis. Congenital CMV represents a distinct clinical entity, with a major risk of neurological sequelae, including hearing impairment.

Serology is mainly used to determine previous exposure to CMV and to assess primary infection during pregnancy. IgM positivity alone is not reliable for diagnosing primary infection, as IgM antibodies may also be present during reactivation. Therefore, IgM results are interpreted together with IgG avidity: the combination of positive IgM and low IgG avidity supports recent primary infection, whereas high IgG avidity generally argues against a recent primary infection. CMV serology is part of the TORCH panel and may be used for screening and monitoring pregnant women to assess the risk of congenital CMV infection in newborns.

VIDIA offers a comprehensive solution for CMV serological diagnostics: ELISA-VIDITEST and MONO-VIDITEST assays for the detection of anti-CMV IgA, IgM and IgG antibodies, including IgG avidity testing and assessment of intrathecal IgG synthesis.

Portfolio

Dostupné assays

Portfolio pro tento patogen průběžně doplňujeme. Napište nám na obchod@vidia.cz a pošleme dostupné varianty.

Časté otázky

Často kladené otázky

What is CMV and why is it tested?

Cytomegalovirus (CMV) is an enveloped DNA virus of the Herpesviridae family. After primary infection it persists in the body for life in a latent form and can reactivate under certain conditions. In immunocompetent individuals the infection often runs asymptomatically or as a mononucleosis-like syndrome, but it has major clinical significance in pregnancy, in recipients of solid organ and hematopoietic stem cell transplants, and in other immunocompromised patients. Serological testing allows determination of specific antibodies IgM, IgG and IgA, evaluation of their dynamics, and for IgG also avidity. This helps distinguish past infection from recent primary infection or possible reactivation, and in defined situations complements direct virus detection by molecular methods.

What is the difference between IgG, IgM and IgA antibody testing for CMV?

The individual antibody classes have different kinetics. IgM typically appears during primary infection within about 1 to 2 weeks and may persist for several months. Its presence alone does not confirm primary infection, because low IgM levels can also occur during reactivation or reinfection. IgG typically appears approximately 2 to 4 weeks after primary infection and then persists long term, usually for life. Seroconversion from IgG negative to positive is strong evidence of recent primary infection. IgA can supplement the serological picture, especially in active infection or reactivation; its result must be evaluated together with IgM, IgG and the clinical context.

What does low versus high IgG avidity mean for CMV?

Avidity expresses the overall binding strength of specific IgG antibodies to the antigen. In the early phase of primary infection, IgG with low avidity is formed; as the humoral response matures, binding strength gradually increases, and after several months high-avidity antibodies predominate. Low avidity therefore supports a diagnosis of recent primary infection, while high avidity indicates infection acquired in the past. In CMV, maturation from low to high avidity typically occurs over approximately 2 to 4 months. Low avidity alone is not absolute proof of the timing of infection, and the result must be interpreted together with IgM, IgG and the time of sample collection.

How is CMV serology used in pregnancy and in the TORCH panel?

In pregnancy, the key question is primarily distinguishing primary CMV infection around the time of conception or in early pregnancy from infection acquired earlier, because primary infection in the mother is associated with a risk of transplacental transmission. Combining IgG and IgM, and in indicated cases determining IgG avidity, allows a substantially more accurate estimate of the timing of infection than IgM alone. High IgG avidity in early pregnancy can, with high probability, rule out recent primary infection, while a combination of IgM and low avidity supports recent primary infection. CMV is also part of TORCH infection diagnostics, a group of infections capable of vertical transmission from mother to fetus.

What type of sample does the CMV test require?

Human serum or plasma is used to determine anti-CMV IgA and IgM. IgG can also be determined in serum and plasma; for kits intended to assess intrathecal synthesis, a paired sample of serum and cerebrospinal fluid (CSF) is tested.

How long does it take to get a result?

ELISA-VIDITEST anti-CMV IgM, IgG and IgA use a unified incubation protocol of 30/30/15 minutes, that is 75 minutes of incubation in total. Sample preparation, washing steps and photometric reading must be added to this; on automated processing these steps run on the analyzer.

Nenašli jste, co hledáte?

Pomůžeme Vám najít vhodné diagnostické řešení

Popište nám, co potřebujete vyšetřit, a náš produktový tým Vám pomůže najít vhodné diagnostické řešení. Odpovíme Vám do 24 hodin.

Preferujete e-mail? Napište nám na obchod@vidia.cz